Immune profiling of canine B cell lymphoma reveals cross-species conservation of prognostic markers.

ABSTRACT: Only 60% of patients with diffuse large B cell lymphoma are cured following standard of care therapies. While immune contexture is associated with outcomes in patients treated with chemotherapy, immune mechanisms driving differential therapeutic responses remain unclear. Here, we undertook a comparative analysis of dogs with spontaneous B cell lymphoma (BCL), which exhibit similar dichotomies in therapeutic outcome, to identify conserved and species-specific transcriptional and circulating biomarkers associated with remission duration. In addition, we compared treatment naive and relapsed samples to determine how treatment impacts immune contexture at the time of treatment failure. Among eighteen client-owned dogs with aggressive BCL undergoing multi-agent chemotherapy, comparative immune

SUBMITTER: Didehvar D 

PROVIDER: S-EPMC12322273 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature